title: Ranibizumab for serous macular detachment in branch retinal vein occlusions.
abstract: BACKGROUND
  The purpose of this study was to compare the efficacy of intravitreal ranibizumab in the treatment of macular edema due to branch retinal vein occlusions (BRVO) with and without serous macular neuroretinal detachment (SMD).
  
  
  METHODS
  Forty-nine eyes of 49 patients with macular edema due to branch retinal vein occlusion (22 with SMD and 27 without SMD) were included in this prospective, parallel-group, comparative study. Intravitreal injection of ranibizumab was administered at baseline. Thereafter patients were followed monthly and further injections were performed in the presence of persistence or recurrence of macular thickening. Flattening of the macula was considered success. At the last visit, best-corrected visual acuity (BCVA), and spectral-domain optical coherence tomography (SD-OCT) quantitative parameters (central subfield thickness, cube volume, average cube thickness) were compared between groups.
  
  
  RESULTS
  In patients with SMD, BCVA and all the SD-OCT quantitative parameters improved significantly after a mean number of 5.0 ranibizumab intravitreal injections through a median follow-up of 12.5 months (range, 7-34). In patients without SMD, all the variables analyzed improved significantly except for the cube volume, after a mean number of 4.3 ranibizumab intravitreal injections through a median follow-up of 10.4 months (range, 6.5-40.2). The numbers of injections were similar in both groups. The final BCVA was better in patients without SMD at baseline but without significant differences in the SD-OCT parameters between groups.
  
  
  CONCLUSIONS
  The presence of SMD may be a baseline predictive factor for ranibizumab treatment outcomes in BRVO patients, with no influence in the number of treatments needed between patients with or without SMD at baseline. Further studies are needed in order to confirm the role of SMD as an independent predicitive factor in cases of BRVO.
authors.affiliation: Department of Ophthalmology, University and Polytechnic Hospital La Fe, Bulevar Sur s/n, 46026 Valencia, Spain.
authors.forename: Roberto
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.forename: Rosa
authors.initials: R
authors.lastname: Dolz-Marco
authors.forename: Diamar
authors.initials: D
authors.lastname: Pardo-López
authors.forename: Sebastián
authors.initials: S
authors.lastname: Martínez-Castillo
authors.forename: Antonio
authors.initials: A
authors.lastname: Lleó-Pérez
authors.forename: J Fernando
authors.initials: JF
authors.lastname: Arévalo
authors.forename: Manuel
authors.initials: M
authors.lastname: Díaz-Llopis
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000188:drug therapy* / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D019233:Retreatment; D044967:Serum; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab